Arella Fabiola, Schlitt Hans J, Riquelme Paloma
Laboratory for Transplantation Research, Department of Surgery, University Hospital Regensburg, Regensburg, Germany.
Transplant Direct. 2025 Sep 2;11(9):e1812. doi: 10.1097/TXD.0000000000001812. eCollection 2025 Sep.
Extracorporeal photopheresis (ECP) is a safe and effective therapy with long-established indications in treating T cell-mediated immune diseases, including steroid refractory graft-versus-host disease and chronic rejection after heart or lung transplantation. The ECP procedure involves collecting autologous peripheral blood leucocytes that are driven into apoptosis before being reinfused intravenously. ECP acts primarily through in situ exposure of recipient dendritic cells and macrophages to apoptotic cells, which then suppress inflammation, promote specific regulatory T-cell responses, and retard fibrosis. Here, we explore the idea that macrophages exposed to apoptotic cell components from photopheresates acquire a tissue-reparative capacity that could be exploited therapeutically. Specifically, we consider innovative applications of ECP in resolving tissue injury after liver transplantation.
体外光化学疗法(ECP)是一种安全有效的治疗方法,在治疗T细胞介导的免疫疾病方面有着长期确立的适应症,包括类固醇难治性移植物抗宿主病以及心脏或肺移植后的慢性排斥反应。ECP程序包括收集自体外周血白细胞,这些白细胞在静脉回输之前被诱导凋亡。ECP主要通过使受体树突状细胞和巨噬细胞原位暴露于凋亡细胞而起作用,然后这些凋亡细胞抑制炎症、促进特异性调节性T细胞反应并延缓纤维化。在此,我们探讨这样一种观点,即暴露于光化学产物凋亡细胞成分的巨噬细胞获得了一种可用于治疗的组织修复能力。具体而言,我们考虑ECP在解决肝移植后组织损伤方面的创新应用。